MASS vs. EYPT, AEHR, ALNT, TRNS, LAB, CTKB, SENS, QSI, FEIM, and QTRX
Should you be buying 908 Devices stock or one of its competitors? The main competitors of 908 Devices include Eyepoint Pharmaceuticals (EYPT), Aehr Test Systems (AEHR), Allient (ALNT), Transcat (TRNS), Standard BioTools (LAB), Cytek Biosciences (CTKB), Senseonics (SENS), Quantum-Si (QSI), Frequency Electronics (FEIM), and Quanterix (QTRX). These companies are all part of the "measuring and control equipment" industry.
908 Devices vs. Its Competitors
Eyepoint Pharmaceuticals (NASDAQ:EYPT) and 908 Devices (NASDAQ:MASS) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, earnings, profitability and analyst recommendations.
Eyepoint Pharmaceuticals currently has a consensus target price of $26.86, suggesting a potential upside of 95.61%. 908 Devices has a consensus target price of $8.00, suggesting a potential downside of 11.80%. Given Eyepoint Pharmaceuticals' higher probable upside, analysts plainly believe Eyepoint Pharmaceuticals is more favorable than 908 Devices.
In the previous week, 908 Devices had 2 more articles in the media than Eyepoint Pharmaceuticals. MarketBeat recorded 4 mentions for 908 Devices and 2 mentions for Eyepoint Pharmaceuticals. 908 Devices' average media sentiment score of 1.19 beat Eyepoint Pharmaceuticals' score of 0.37 indicating that 908 Devices is being referred to more favorably in the news media.
908 Devices has a net margin of -30.54% compared to Eyepoint Pharmaceuticals' net margin of -337.93%. 908 Devices' return on equity of -24.30% beat Eyepoint Pharmaceuticals' return on equity.
99.4% of Eyepoint Pharmaceuticals shares are held by institutional investors. Comparatively, 88.1% of 908 Devices shares are held by institutional investors. 4.5% of Eyepoint Pharmaceuticals shares are held by company insiders. Comparatively, 23.7% of 908 Devices shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
908 Devices has higher revenue and earnings than Eyepoint Pharmaceuticals. 908 Devices is trading at a lower price-to-earnings ratio than Eyepoint Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Eyepoint Pharmaceuticals has a beta of 1.95, suggesting that its share price is 95% more volatile than the S&P 500. Comparatively, 908 Devices has a beta of 0.46, suggesting that its share price is 54% less volatile than the S&P 500.
Summary
908 Devices beats Eyepoint Pharmaceuticals on 11 of the 17 factors compared between the two stocks.
Get 908 Devices News Delivered to You Automatically
Sign up to receive the latest news and ratings for MASS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding MASS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
908 Devices Competitors List
Related Companies and Tools
This page (NASDAQ:MASS) was last updated on 10/3/2025 by MarketBeat.com Staff
